Advertisement

Topics

Pfizer: FDA Oks First Epoetin Alfa Biosimilar For Treatment Of Anemia

23:40 EDT 15 May 2018 | FinanzNachrichten

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced the United States Food and Drug Administration approved Retacrit orepoetin alfa-epbx, a biosimilar to Epogen and Procrit (epoetin alfa), for a...

Original Article: Pfizer: FDA Oks First Epoetin Alfa Biosimilar For Treatment Of Anemia

NEXT ARTICLE

More From BioPortfolio on "Pfizer: FDA Oks First Epoetin Alfa Biosimilar For Treatment Of Anemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...